Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Mike Baker who wrote (2502)	6/1/1999 7:23:00 AM
From: 2MAR$	Read Replies (1) \| Respond to of 4140

(BSNS WIRE) Sunrise Technologies International, Inc. Names New Vice Pres Sunrise Technologies International, Inc. Names New Vice President Finance-CFO Business Editors & Health/Medical Writers FREMONT, Calif.--(BW HealthWire)--June 1, 1999--Sunrise Technologies International, Inc. (NASDAQ/NMS:SNRS), today announced the appointment of Peter E. Jansen as the Company's new Vice President Finance and Chief Financial Officer. Jansen has over 30 years of domestic and international business experience in biotechnology, pharmaceutical, petrochemical and heavy equipment companies. Most recently, Jansen has served as Chief Financial Officer at CoCensys, Inc., an Irvine California biopharmaceutical company. He also was founder and CEO of PhytoMedica Health Products, Inc. in Rockville, Maryland, which was later reorganized into a joint venture with a similar company. Jansen previously was Senior Vice President and CFO of Genelabs Technologies, Inc. From 1975 to 1992, Jansen was a senior financial executive and company officer at Abbott Laboratories, in North Chicago, Illinois where his latest position was Assistant Corporate Treasurer. He earlier served in a senior financial role at Eli Lilly and Industrias Villares, S.A. in Sao Paulo, Brazil. He earned his MBA from Baylor University where he was a Fulbright Scholar. "We are extremely pleased that Peter has joined us at Sunrise. His experience in both small companies and multi-national firms will help us immensely as the Company enters its phase of rapid growth," said C. Russell Trenary III, President and Chief Executive Officer of Sunrise. Sunrise Technologies International, Inc., which is based in Fremont, is a refractive surgery company that produces and markets high technology products revolutionizing treatment methods in eye care. The Company develops Holmium laser-based systems, which utilize a patented process for shrinking collagen developed by Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic conditions. These Systems(1) incorporate a non-contract simultaneous application for correction of hyperopia (farsightedness), presbyopia (loss of focus due to natural aging), and overcorrection resulting from PRK and LASIK treatments for myopia. The Ophthalmic Devices Panel of the United States Food and Drug Administration is scheduled to review the Company's Premarket Approval (PMA) application at its July 22-23 meeting. The Panel will review the PMA for the Sunrise LTK(TM) System for the treatment of hyperopia (+.75 to +2.50 diopters). Except for historical information, this news release contain certain forward-looking statements that involve risk and uncertainties which may cause actual results to differ materially from the statements made, including market potential, regulatory clearances, business growth and other risks listed from time to time in the Company's Securities and Exchange Commission (SEC) filings. These forward-looking statements represent the Company's judgement, as of the date of this release, and the Company disclaims any intent or obligation to update these forward-looking statements. (1) Caution-Investigational Device: Federal law restricts this device to investigational use in the U.S. Internet users can access Sunrise's World Wide Web site at sunrise-tech.com. --30--slt/sf* CONTACT: Sunrise Technologies International, Inc., Fremont Investor Relations Susan Lorigan, 510/623-9001 Ed Coghlan, 510/771-2399 KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY MANAGEMENT CHANGES Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com